More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...
Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.
Antimitochondrial antibodies can be detected in patients with systemic lupus erythematosus (SLE) and appear prognostic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results